Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity (Q37978441)

26 August 2017

0 references

Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

0 references

1 reference

J J Ott

1

1 reference

26 August 2017

G A Stevens

series ordinal

2

1 reference

26 August 2017

J Groeger

series ordinal

3

1 reference

26 August 2017

S T Wiersma

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

24 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

30

1 reference

26 August 2017

2212-2219

1 reference

26 August 2017

12

1 reference

Risks of chronicity following acute hepatitis B virus infection: a review

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Treatment of hepatitis B: who, when, and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Global cancer incidence and mortality caused by behavior and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Hepatitis B virus infection: epidemiology and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

The prevalence of hepatitis B virus infection in the United States in the era of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Twelve-year follow-up study of hepatitis B immunization of Senegalese infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Surveillance and epidemiology of hepatitis B and C in Europe - a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Natural History and Clinical Consequences of Hepatitis B Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Hepatitis B virus: significance of genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

Chronic disease mortality associated with infectious agents: a comparative cohort study of migrants from the Former Soviet Union in Israel and Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.116

10.1016/J.VACCINE.2011.12.116

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference